Hamburg, Germany

Charlotte Ahle

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Beiersdorf Ag. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Charlotte Ahle: Innovator in Oligonucleotide Detection

Introduction

Charlotte Ahle is a prominent inventor based in Hamburg, Germany. She has made significant contributions to the field of biotechnology, particularly in the detection of bacterial pathogens. Her innovative work has led to the development of novel oligonucleotides that are crucial for identifying Staphylococcus, a common and potentially harmful bacterium.

Latest Patents

Charlotte holds a patent for her invention titled "Novel Oligonucleotides for Detecting Staphylococcus." This patent represents her commitment to advancing medical diagnostics and improving public health outcomes. She has 1 patent to her name, showcasing her expertise and dedication to innovation.

Career Highlights

Charlotte is currently employed at Beiersdorf AG, a leading global company known for its skincare products. Her role at Beiersdorf AG allows her to apply her scientific knowledge and contribute to the development of effective health solutions. Her work is instrumental in enhancing the company's research capabilities in biotechnology.

Collaborations

Charlotte collaborates with talented colleagues, including Jennifer Huepeden and Heike Foelster. These partnerships foster a creative environment that encourages the exchange of ideas and the pursuit of groundbreaking research.

Conclusion

Charlotte Ahle is a remarkable inventor whose work in oligonucleotide detection is paving the way for advancements in medical diagnostics. Her contributions to Beiersdorf AG and her collaborations with fellow researchers highlight her commitment to innovation and public health.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…